Citigroup Inc. Has $4.16 Million Holdings in Organon & Co. (NYSE:OGN)

Citigroup Inc. lessened its position in shares of Organon & Co. (NYSE:OGN – Get Rating) by 5.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 148,861 shares of the company’s stock after selling 7,851 shares during the quarter. Citigroup Inc.’s holdings in Organon & Co. were worth $4,158,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Ellevest Inc. grew its position in shares of Organon & Co. by 311.9% during the 3rd quarter. Ellevest Inc. now owns 1,145 shares of the company’s stock worth $27,000 after buying an additional 867 shares during the period. Belpointe Asset Management LLC acquired a new stake in Organon & Co. in the 4th quarter valued at $28,000. Massmutual Trust Co. FSB ADV grew its position in Organon & Co. by 132.2% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 1,066 shares of the company’s stock valued at $30,000 after purchasing an additional 607 shares during the period. Romano Brothers AND Company acquired a new stake in Organon & Co. in the 4th quarter valued at $31,000. Finally, Glassman Wealth Services lifted its stake in Organon & Co. by 63.8% during the 4th quarter. Glassman Wealth Services now owns 1,155 shares of the company’s stock valued at $32,000 after acquiring an additional 450 shares in the last quarter. Institutional investors and hedge funds own 75.74% of the company’s stock.

Organon & Co. Price Performance

NYSE OGN opened at $20.43 on Monday. The stock has a market capitalization of $5.21 billion, a price-to-earnings ratio of 7.00, a PEG ratio of 0.88 and a beta of 0.77. Organon & Co. has a one year low of $20.12 and a one year high of $39.09. The business’s fifty day moving average is $22.72 and its 200-day moving average is $25.72.

Organon & Co. (NYSE:OGN – Get Rating) last announced its quarterly earnings data on Thursday, May 4th. The company reported $1.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.18 by ($0.10). Organon & Co. had a net margin of 12.14% and a negative return on equity of 119.00%. The firm had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.54 billion. During the same quarter in the prior year, the firm posted $1.65 earnings per share. The company’s revenue was down 1.9% on a year-over-year basis. Research analysts expect that Organon & Co. will post 4.22 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 15th. Shareholders of record on Monday, May 15th will be issued a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 5.48%. The ex-dividend date of this dividend is Friday, May 12th. Organon & Co.’s payout ratio is presently 38.36%.

Analysts Set New Price Targets

Separately, Raymond James assumed coverage on Organon & Co. in a research note on Wednesday, March 15th. They set an “outperform” rating and a $33.00 price objective on the stock.

About Organon & Co.

(Get Rating)

Organon & Co, a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.